Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Volumn 4, Issue , 2016, Pages 21-27

  Skrahin, Aliaksandr ^a,b   Jenkins, Helen E ^c,d,f   Hurevich, Henadz ^a   Solodovnikova, Varvara ^a   Isaikina, Yanina ^e   Klimuk, Dzmitri ^a   Rohava, Zoya ^a   Skrahina, Alena ^a  

^a National Research and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

^b BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Haematology and Immunology   (Belarus)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Extensively drug resistant; Mesenchymal stromal cells; Outcomes; Treatment

Indexed keywords

EID: 84977485459     PISSN: None     EISSN: 24055794     Source Type: Journal    
DOI: 10.1016/j.jctube.2016.05.003     Document Type: Article

References (44)

1. World Health Organization. Global tuberculosis report 2014. Geneva: 2014 Accessed on: 10 August 2015. Report No: WHO/HTM/TB/2014.08. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1.
2. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38(3):516-528.
3. Lew W, Pai M, Oxlade O, Martin D, Menzies D Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008, 149(2):123-134.
4. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made?. Eur Respir J 2015, 45(1):150-160.
5. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014, 14(4):327-340.
6. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013, 91(1):36-45.
7. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2(2):108-122.
8. Hall RD, Gray JE, Chiappori AA Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control: J. Moffitt Cancer Cent 2013, 20(1):22-31.
9. Sinclair K, Yerkovich ST, Chambers DC Mesenchymal stem cells and the lung. Respirology 2013, 18(3):397-411.
10. Barnes PF. Immunotherapy for tuberculosis: wave of the future or tilting at windmills?. Am J Respir Crit Care Med 2003, 168(2):142-143.
11. Auletta JJ, Deans RJ, Bartholomew AM Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119(8):1801-1809.
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: 2008. [accessed 10.08.15]. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
13. Ralph AP, Ardian M, Wiguna A, et al. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 2010, 65(10):863-869.
14. Dunn OJ. Multiple comparison among means. J Am Stat Assoc 1961, 56:52-64.
15. Critchley JA, Young F, Orton L, Garner P Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13(3):223-237.
16. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208(2):199-202.
17. Misra UK, Kalita J, Nair PP Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci 2010, 293(1-2):12-17.
18. Bourigault ML, Vacher R, Rose S, et al. Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. Am J Clin Exp Immunol 2013, 2(1):124-134.
19. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011, 25(4):648-654.
20. Van Linthout S, Savvatis K, Miteva K, et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011, 32(17):2168-2178.
21. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010, 182(8):1047-1057.
22. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28(12):2229-2238.
23. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010, 138(4):965-972.
24. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179(3):1855-1863.
25. Zhao F, Zhang YF, Liu YG, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 2008, 40(5):1700-1705.
26. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003, 100(14):8407-8411.
27. Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001, 128(24):5181-5188.
28. Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008, 177(7):701-711.
29. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015, 3(1):24-32.
30. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014, 15:39.
31. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013, 143(6):1590-1598.
32. Oswald J, Boxberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22(3):377-384.
33. Spees JL, Olson SD, Whitney MJ, Prockop DJ Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci USA 2006, 103(5):1283-1288.
34. Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012, 302(9):L829-L837.
35. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39(2):573-576.
36. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008, 14(2):181-187.
37. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169(1):12-20.
38. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108(7):863-868.
39. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5(1):54-63.
40. Wong AP, Dutly AE, Sacher A, et al. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. Am J Physiol Lung Cell Mol Physiol 2007, 293(3):L740-L752.
41. Wong AP, Keating A, Lu WY, et al. Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium. J Clin Investig 2009, 119(2):336-348.
42. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144(9):650-659.
43. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015, 3(3):201-209.
44. Anderson LF, Tamne S, Watson JP, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013, 18(40).